Norway
Otivio AS, founded in 2010 and headquartered in Oslo, Norway, operates in the Biotechnology, Health Care, and Medical Devices sectors. The company has expanded with subsidiaries in Denmark and Germany as of 2021.
The company's flagship offering, FlowOx™, is a CE-certified, non-invasive medical device designed for both hospital and home applications. It is primarily used to treat peripheral arterial disease (PAD)-related issues, such as chronic ulcers and reduced mobility. Clinical and observational studies have confirmed the therapeutic efficacy of FlowOx™. Emerging data also hint at its potential in alleviating symptoms of Multiple Sclerosis (MS).
Notably, the device employs intermittent negative pressure (INP) to enhance blood circulation and oxygen supply to the lower extremities, offering easy and comfortable use. Otivio AS is currently seeking partners to drive commercial development forward, presenting an attractive opportunity in a clinical area with unmet needs.
Protégé Biomedical